| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281733 | Clinical Gastroenterology and Hepatology | 2013 | 10 Pages |
Abstract
Chelating agents are effective therapies for most patients with Wilson disease; D-penicillamine and trientine produce comparable outcomes, although D-penicillamine had a higher rate of adverse events. Few patients receiving chelation therapy had neurologic deterioration, which occurred more frequently in patients who received trientine.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Karl Heinz Weiss, Florentine Thurik, Daniel Nils Gotthardt, Mark Schäfer, Ulrike Teufel, Franziska Wiegand, Uta Merle, Daniela Ferenci-Foerster, Andreas Maieron, Rudolf Stauber, Heinz Zoller, Hartmut H. Schmidt, Ulrike Reuner, Harald Hefter,